Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer

Donate-Moreno, María J.; Lorenzo-Sánchez, Marta Victoria; Migallón, I. Díaz de Mera-Sánchez; Herraiz-Raya, L.; Esper-Rueda, J.A.; Legido-Gómez, Óscar; Rico-Marco, Saúl; Salinas-Sánchez, Antonio S.

doi:10.1016/j.acuroe.2020.11.009

Cited by 7 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified a total of 72 records from the initial database search, of which 49 studies were from PubMed database, 21 studies were from EMBASE database and 2 studies were from the Cochrane library database. After excluding duplications and screening the full-texts, 11 studies (12,15,16,(20)(21)(22)(23)(24)(25)(26)(27) were included in this systematic review, and 10 (12, 15, 20-27) of which were enrolled in the meta-analysis. Patients in 7 studies (12,15,(20)(21)(22)(23)26) were diagnosed with mCRPC, and those in the other 3 studies (24,25,27) were diagnosed with nmPCa.…”

Section: Literature Searchmentioning

confidence: 99%

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis

Zhou²,

Liu³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundA novel inflammatory marker called the systemic immune-inflammation index (SII) was applied to predict the prognosis of different cancers. However, the role of SII in prostate cancer (PCa) remains unclear. This systematic review aims to explore the prognostic role of SII in different stage PCa.MethodsWe comprehensively searched three public databases: PubMed, EMBASE, and the Cochrane Library. The hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were extracted to evaluate the association between SII and the prognosis and clinicopathological characteristics in different stage PCa patients.ResultsTen studies and 7,986 patients were enrolled in our meta-analysis, 1,442 patients were diagnosed with metastatic-castration resistant prostate cancer (mCRPC), and 6544 patients were diagnosed with non-metastatic prostate cancer (nmPCa). According to the pooled results, we found that a high SII was associated with worse overall survival (OS) in mCRPC patients (HR = 1.94, 95% CI: 1.26–3.01, p = 0.003), and a high SII was associated with biochemical recurrence-free survival (BFS) in nmPCa patients (HR = 1.85, 95% CI: 1.06–3.24, p = 0.031). But there was no significant association observed between SII and progression-free survival (PFS) in mCRPC patients (HR = 1.90, 95% CI: 0.87–4.14, p = 0.107). And we found that the high SII was associated with advanced tumor stage of PCa (OR = 2.19, 95% CI: 1.11–4.33, p = 0.024), presence of lymph node involvement (OR = 2.72, 95% CI: 1.96–3.76, p < 0.001) and Gleason score (OR = 1.27, 95% CI: 1.13–1.44, p < 0.001).ConclusionHigh SII was associated with bad OS in mCRPC patients, and associated with bad BFS and some adverse pathological features in nmPCa patients. We think SII can be a prognostic predictor for PCa patients. The application of SII will advance the diagnosis and treatment of different stage prostate cancer.

show abstract

Section: Literature Searchmentioning

confidence: 99%

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis

Zhou²,

Liu³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…In a prospective cohort-study including 80 patients, Donate-Moreno et al in 2020 investigated inflammatory markers in mCRPC under various treatment and could show a negative correlation of NLR, PLR and SII with survival time (Donate-Moreno et al 2020). Yamada et al in 2020 retrospectively analyzed 196 patients with mCRPC from multiple institutions and built an inflammation index based on derived neutrophiles/(leukocytes minus neutrophils) ratio (dNLR) and LDH.…”

Section: Discussionmentioning

confidence: 99%

“…The abundance of (inflammatory) biomarkers studied has led to the combination of biomarkers and combined prognostic scores like the modified Glasgow Prognostic Score (mGPS), the neutrophile-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio and the systemic immune-inflammation index (SII) as well in urological as in non-urological malignancies (Lee et al 2015;Dolan et al 2018;Wang et al 2021). Recently, several studies provided evidence on the prognostic value of inflammatory markers in patients with mCRPC under various treatments including docetaxel (Donate-Moreno et al 2020;Stangl-Kremser et al 2020;Yamada et al 2020). This study's aim was to investigate pre-treatment inflammatory biomarkers in a real-world cohort and add evidence on their suitability as predictors for treatment response and prognostic factors for survival in men with mCRPC receiving docetaxel chemotherapy in general and as firstline treatment.…”

Section: Introductionmentioning

confidence: 99%

Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort

Neuberger

Goly

Skladny

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Advances in therapy of metastatic castration-refractory prostate cancer (mCRPC) resulted in more therapeutic options and led to a higher need of predictive/prognostic biomarkers. Systemic inflammatory biomarkers could provide the basis for personalized treatment selection. This study aimed to assess the modified Glasgow Prognostic Score (mGPS), the neutrophile-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR) and the systemic immune-inflammation index (SII) in men with mCRPC under docetaxel. Methods Patients with mCRPC and taxane chemotherapy at a tertiary care centre between 2010 and 2019 were screened retrospectively. The biomarkers mGPS, NLR, PLR and SII were assessed and analyzed for biochemical/radiologic response and survival. Results We included 118 patients. Of these, 73 (61.9%) had received docetaxel as first-line, 31 (26.2%) as second-line and 14 (11.9%) as third-line treatment. For biochemical response, mGPS (odds ratio (OR) 0.54, p = 0.04) and PLR (OR 0.63, p = 0.04) were independent predictors in multivariable analysis. SII was significant in first-line cohort only (OR 0.29, p = 0.02). No inflammatory marker was predictive for radiologic response. In multivariable analysis, mGPS and NLR (hazard ratio (HR) 1.71 and 1.12, both p < 0.01) showed significant association with OS in total cohort and mGPS in the first-line cohort (HR 2.23, p < 0.01). Haemoglobin (Hb) and alkaline phosphatase (AP) showed several significant associations regarding 1 year, 3 year, OS and biochemical/radiologic response. Conclusions Pre-treatment mGPS seems a promising prognostic biomarker. A combination of mGPS, NLR and further routine markers (e.g., Hb and AP) could yield optimized stratification for treatment selection. Further prospective and multicentric assessment is needed.

show abstract

“…However, these in ammation-based markers integrated only two types of in ammatory cells. SII, which is based on neutrophil, platelet and lymphocyte counts, was rst used in hepatocellular carcinoma and was considered a predictor of several types of solid tumours [12,13,30]. In this study, we investigated the preoperative nutrition-and in ammation-based factors, PNI and SII, in high-risk NMIBC patients who received intravesical instillation of BCG after TURBT.…”

Section: Discussionmentioning

confidence: 99%

“…Growing evidence has shown that a low PNI score is signi cantly associated with major postoperative complications and poor prognosis [10,11]. The systemic immune-in ammation index (SII) was rst used to evaluate hepatocellular carcinoma and was considered a predictor of several solid tumours, particularly prostate cancer and metastatic non-clear cell renal cell carcinoma [12,13]. The preoperative PNI and SII are identi ed as effective tumour biomarkers that have important signi cance in the prognosis of many malignant tumours [14,15].…”

Section: Introductionmentioning

confidence: 99%

Preoperative Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Predicting the Long-Term Recurrence-Free Survival of Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After Transurethral Resection of a Bladder Tumour: A Cohort Study

Jia

Shang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background The predictive values of preoperative prognostic nutritional index (PNI) and systemic immune-inflammation index (SII) for long-term recurrence-free survival (RFS) in high-risk non-muscle-invasive bladder cancer (NMIBC) have not been fully elucidated. Hence, this study aimed to examine the associations between PNI and SII as well as RFS in patients with high-risk NMIBC who received intravesical instillation of Bacillus Calmette–Guerin (BCG) after transurethral resection of bladder tumour (TURBT).Methods We retrospectively collected data on 387 high-risk NMIBC patients between January 2004 and December 2014. Preoperative PNI was calculated as albumin concentration (g/L)+5×total lymphocyte count (109/L), while preoperative SII was defined as neutrophil count (109/L)×platelet count (109/L)/lymphocyte count (109/L). The optimal cut-off values of PNI and SII were determined via a receiver operating characteristic analysis. RFS was evaluated via a Kaplan–Meier analysis. Between-group differences were compared using the log-rank test. Univariate and multivariate Cox regression analyses were performed to assess the predictive values of PNI and SII for RFS.Results Patients were divided into two groups according to the cut-off values of PNI (<50.17 vs ≥50.17) and SII (<467.76 vs ≥467.76). Kaplan-Meier analyses revealed that low PNI and high SII were associated with poor RFS in patients with high- and higher-risk NMIBC. Furthermore, based on univariate and multivariate Cox regression analyses, PNI and SII were independent predictive factors of RFS in patients with high-risk NMIBC.Conclusion Preoperative PNI and SII are simple, noninvasive, inexpensive and useful tools for predicting long-term RFS among patients with high-risk NMIBC who received intravesical instillation of BCG after TURBT.

show abstract

Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer

Cited by 7 publications

References 27 publications

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis

Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort

Preoperative Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Predicting the Long-Term Recurrence-Free Survival of Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After Transurethral Resection of a Bladder Tumour: A Cohort Study

Contact Info

Product

Resources

About